Fuller Company expands portfolio with acquisition of Adhezion Biomedical
12 Jul 2023
Acquisition
Fuller Company has acquired Adhezion Biomedical, a US medical adhesives company with customers in more than 40 countries.
The acquisition of Adhezion ─ which manufactures and distributes highly differentiated, proprietary cyanoacrylate technologies for surgical care, wound management, and infection prevention in healthcare settings ─ builds a platform of scale for H.B. Fuller in the topical skin bonding market, adding to capabilities attained from the company’s purchase of Tissue Seal in 2021 and providing vertically integrated adhesive manufacturing and packaging capability. The acquisition decisively positions H.B. Fuller for expansion in the medical adhesives industry and creates a solid, unique platform from which to scale and innovate in the healthcare adhesives space.
Jim East, executive vice president, Hygiene, Health, and Consumable Adhesives, said: “This is a strategic move in support of our long-term growth strategy. H.B. Fuller products have been used around the world in medical applications for more than two decades, enabling new ideas and accelerating innovation. With our acquisition of Adhezion Biomedical, we will not only open new markets and diversify our portfolio, we will significantly strengthen our capabilities in the medical adhesives space, representing a milestone in our commitment to deliver greater value to our customers around the world.”
With a team of approximately 50 employees, Adhezion Biomedical will operate within H.B. Fuller’s existing Hygiene, Health, and Consumable Adhesives global business unit to accelerate growth with new medical grade technology, in-depth application expertise, and reinforced ability to certify new innovations in the healthcare industry around the world.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.